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ABSTRACT 41	
Background. The deficiency of α1-antitrypsin (AAT) is secondary to misfolding and 42	
polymerization of the abnormal Z-AAT in liver cells and is associated with lung emphysema. 43	
Alveolar macrophages (AM) produce AAT, however it is not known if Z-AAT can polymerize in 44	
AM, further decreasing lung AAT and promoting lung inflammation. 45	
Aims. To investigate if AAT polymerizes in AM and to study the possible relation between 46	
polymerization and degree of lung inflammation. 47	
Methods. Immunohistochemical analysis with 2C1 monoclonal antibody specific for polymerized 48	
AAT was performed in sections of: 9 lungs from individuals with AAT deficiency (AATD) and 49	
severe COPD, 35 smokers with normal AAT levels of which 24 with severe COPD and 11 without 50	
COPD, and 13 non-smokers. AM positive for AAT polymers were counted and expressed as 51	
percentage of total AM in lung.  52	
Results. AAT polymerization was detected in [27(4-67)%] of AM from individuals with AATD but 53	
also in AM from smokers with normal AAT with [24(0-70)%] and without [24(0-60)%] COPD, but 54	
not in AM from non-smokers [0(0-1.5)%] (p<0.0001). The percentage of AM with polymerized 55	
AAT correlated with pack-years smoked (r=0.53, p=0.0001), FEV1/FVC (r=-0.41, p=0.005), 56	
number of CD8+T-cells and neutrophils in alveolar walls (r=0.51, p=0.002; r=0.31, p=0.05 57	
respectively).  58	
Conclusions. Polymerization of AAT in alveolar macrophages occurs in the lungs of individuals 59	
with AATD but also in smokers with normal AAT levels with or without COPD. Our findings 60	
highlight the similarities in the pathophysiology of COPD in individuals with and without AATD, 61	
adding a potentially important step to the mechanism of COPD. 62	
 63	
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INTRODUCTION 66	
α1-antitrypsin (AAT) is the archetypal member of the serine protease inhibitor (SERPIN) 67	
superfamily. Severe deficiency of this protein, secondary to an inherited disorder, is linked to the 68	
development of early onset emphysema. About 95% of the significant clinical deficiency is caused 69	
by the Z variant of the protein that results from the substitution of a glutamic acid (Glu) by a lysine 70	
(Lys) at position 342.1-5 Approximately 0.06% of individuals of North European descent have 71	
severe deficiency of AAT with plasma levels of less than 0.2 g/L.1-5 The Glu to Lys substitution in 72	
Z-AAT results in abnormal protein folding within the endoplasmic reticulum (ER) of the 73	
hepatocyte, protein polymerization and intracellular retention with consequent low AAT serum 74	
levels.1-5 Thus the effect of the Z mutation is not a failure of synthesis (Z-AAT is processed 75	
normally until it reaches the final stage of the hepatocyte ER pathway), but a failure in folding and 76	
secretion. About 85% of the Z-AAT is removed by ER-associated degradation or aggregates to 77	
form polymers while 15% is secreted in the serum.1-6 78	
Polymerization of Z-AAT in the liver causes a “toxic gain of function” within hepatocytes3, with 79	
ER stress and activation of NF-κB7-9 triggering an inflammatory reaction in response to protein 80	
misfolding and polymerization in the hepatocytes that predispose to neonatal hepatitis and liver 81	
cirrhosis.10,11 82	
Epithelial barrier macrophages such as alveolar macrophages, intestinal and epithelial macrophages 83	
and breast milk macrophages, along with blood monocytes, are also important producers of AAT in 84	
their local milieu.12-14 To a minor extent other cells in the lung including lung epithelial cells, 85	
bronchial epithelial cells (BECs), endothelial cells, the human A549 cell line of alveolar epithelial 86	
cells in the lung and polymorphonuclear leukocytes and neutrophils, have been found to also 87	
produce AAT.15-19 Alveolar macrophages develop from fetal liver under the control of GM-CSF in 88	
the first days of life, paralleling the development of the alveoli and then maintain themselves by in 89	
situ self-renewal.20-22 Perhaps, due to their different origin, there is an important difference in 90	
production of AAT between blood monocytes (which produce three fold less AAT) and alveolar 91	
macrophages14, suggesting that alveolar macrophages are preprogramed by their liver origin or that, 92	
once in the lung milieu, they up-regulate AAT gene expression.  93	
Alveolar macrophages can produce relatively large amounts of AAT directly into the lung but, as 94	
with hepatocytes, the production and secretion of AAT is regulated by inflammatory mediators such 95	
as Lipopolysaccharides (LPS) and the acute phase cytokine Interleukin IL-6. The synthesis of AAT 96	
is also modulated by the presence of elastase in a dose and time dependent way.23 Under these 97	
stimuli wild type PiMM AAT monocytes can increase the synthesis and secretion of AAT by up to 98	
10 fold.14  99	
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It would seem that the normal production of AAT by alveolar macrophages, potentially increased 100	
under the modulation of inflammatory mediators and elastase, could well polymerize in the ER of 101	
alveolar macrophages in PiZZ individuals, a possibility that has never been studied in human lung 102	
tissue. If that were the case, AAT polymerization in alveolar macrophages will not only contribute 103	
to loss of AAT function due to diminished secretion in the alveoli, but also, as in the liver, to “toxic 104	
gain of function” with all its complex and detrimental consequences. 105	
It was the aim of our study to assess whether alveolar macrophages in the lung tissue from 106	
individuals with PiZZ AAT deficiency formed AAT polymers and if polymerization could be 107	
related to inflammation within the lung. For this purpose, we studied lung sections from individuals 108	
with COPD with AAT deficiency undergoing lung transplantation and compared them with lungs of 109	
smokers with COPD and normal AAT (“usual” COPD), smokers without COPD, and non-smokers.  110	
The results of this investigation have been presented in abstract form.24 111	
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METHODS 113	
 114	
Subject Characteristics 115	
We studied the tissues from the lungs of 33 patients undergoing lung transplantation for severe 116	
COPD: 9 had PiZZ α1-antitrypsin deficiency (COPD with AATD) and 24 had normal levels of 117	
AAT (“usual” COPD). AATD was confirmed by serum levels, together with 118	
genotyping/phenotyping in all cases. Sections from the lungs of 11 smokers with normal lung 119	
function and 13 non-smoking subjects, who had lung resection for solitary nodules, were included 120	
for comparison. All 57 subjects underwent pulmonary function tests prior to surgery and provided 121	
informed written consent. The study conformed to the Declaration of Helsinki. All aspects of this 122	
study were approved by the local Ethics Committee (reference number 0006045). Details are 123	
reported in the Online Supplement.  124	
Histochemistry, immunohistochemistry and morphometric analysis 125	
Lung tissue preparation, histochemistry and immunohistochemistry were performed as previously 126	
described and detailed in the Online Supplement.25,26  127	
The lung tissue specimens were fixed in formalin, embedded in paraffin wax and cut. At least three 128	
lung sections per case were stained with periodic acid-Schiff (PAS) and immunostained  according 129	
to the standard peroxidase-antiperoxidase method with a commercial polyclonal anti-AAT antibody 130	
recognizing total AAT (both native and polymerized, IR505 Dako, Denmark) and with the specific 131	
monoclonal antibody 2C1 that recognizes intracellular AAT polymers but not native (monomeric), 132	
reactive loop cleaved or latent AAT.27 Negative controls for nonspecific binding were processed 133	
either omitting the primary antibody or using isotype IgG and revealed no signal.  134	
To quantify AAT positive alveolar macrophages, PAS positive inclusions in alveolar macrophages 135	
and AAT polymerized positive alveolar macrophages at least 20 to 40 non consecutive high-power 136	
fields (HPF) and at least 100 macrophages inside the alveolar spaces were evaluated for each 137	
subject. The results were expressed as percentage of positive macrophages over the total number of 138	
macrophages examined.25,26 Alveolar macrophages were defined as mononuclear cells with a well-139	
represented cytoplasm, present in the alveolar spaces. 140	
As positive control for AAT polymer staining we examined 6 liver samples from PiZZ patients who 141	
underwent liver transplantation related to AATD. 5 µm sections were stained with PAS and the 142	
specific monoclonal antibody 2C1 to detect AAT polymerization, following the same protocol used 143	
for pulmonary tissue. 144	
Neutrophils, macrophages, T CD4+ lymphocytes, T CD8+ lymphocytes and B lymphocytes were 145	
identified by immunohistochemistry and counted in the alveolar walls in order to evaluate a 146	
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possible correlation between AAT (native and polymerized) and the degree of lung 147	
inflammation.25,26 Details are reported in the Online Supplement.  148	
Using the semi quantitative method described by us we assessed the diseased score (inflammation, 149	
muscle, wall thickness) in all airways less than 2 mm in diameter. Each bronchioles 2 mm and less 150	
in diameter was examined separately for the presence of inflammatory cell infiltrate, fibrosis and 151	
smooth muscle hypertrophy. For each airway, a score from 0 (normal) to 3+ (most abnormal) was 152	
assigned for each pathological feature. Scores for individual features were summed and expressed 153	
as percentage of maximal possible score.28 154	
A macroscopic quantification of emphysema was performed in all explanted lungs, using the 155	
method of a Heard.29 Because lungs were not fixed in inflation at a constant pressure we were not 156	
able to use mean linear intercept (Lm) for the microscopic quantitation of the emphysema (air space 157	
size). We did instead a semiquantitative score of the extent of microscopic emphysema (0,1,2,3+) in 158	
every slide available in all cases were added and expressed as percentage of the maximal possible 159	
score.28  160	
The possible relationship between AAT polymerization and inflammatory response was also 161	
examined in liver tissue. From each liver surgical sample, two consecutive sections of 5 µm thick 162	
were cut and stained with 2C1 antibody to identify polymers in one section (following the same 163	
protocol used for pulmonary tissue) and with CD45 antibody to identify total leukocytes in the other 164	
consecutive section. An intensity score from 0 to 3 for the extent of polymerization and of CD45 165	
was graded in 50 fields for slide pair. 166	
All analyses were performed using a Leica light microscope and video recorder linked to a 167	
computerized image analysis system (Leica LAS w3.8). 168	
Statistical analysis 169	
Group differences were evaluated by analysis of variance (ANOVA) and unpaired Student t test for 170	
clinical data, and by Kruskal–Wallis test and Mann–Whitney U test for morphological data. 171	
Correlation coefficients were calculated by the Spearman rank method. P values of 0.05 or less 172	
were considered to indicate statistical significance. Details are reported in the Online Data 173	
Supplement. 174	
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RESULTS 176	
 177	
Clinical Characteristics 178	
 179	
Nine patients transplanted for severe COPD had low serum AAT levels consistent with severe 180	
AATD and confirmed by either genotyping or phenotyping (8 ZZ and 1 ZI). All patients with 181	
“usual” COPD, smokers without COPD and non-smokers, had a normal a1 band on protein 182	
electrophoresis. 183	
The clinical characteristics of the subjects in this study are shown in Table 1. There were no 184	
differences in age and amount smoked (14% current smokers and 86% recent ex-smokers). The 185	
values of FEV1 (% predicted) and FEV1/FVC (%) were similarly decreased in the COPD with 186	
AATD and in “usual” COPD, whereas they were in the normal range in smokers without COPD 187	
and non-smokers. 188	
 189	
Histochemical and immunohistochemical findings 190	
 191	
Positive staining with anti-AAT antibody IR505, which stains both native and polymerized AAT, 192	
was observed mainly in alveolar macrophages (AM) and occasionally in the alveolar walls (Fig.1 193	
panels A-B). There was no significant difference in the percentage of alveolar macrophages positive 194	
for total (native and polymerized) AAT between: COPD with AATD, “usual” COPD, smokers 195	
without COPD and non-smokers (Fig.1, C). 196	
The percentage of PAS positive AM was increased not only in individuals with AATD, but also in 197	
smokers with or without COPD and normal AAT levels compared to non-smokers, where no PAS 198	
positive intracellular inclusion were see (Fig.2). Furthermore, the percentage of periodic acid-Schiff 199	
(PAS) positive AM was also increased in smokers with “usual” COPD compared to smokers 200	
without COPD. (Fig. 2) The PAS inclusions were similar to those seen in the liver from individuals 201	
with PiZZ AATD (Fig.3 A-B). The use of the polymer specific 2C1 monoclonal antibody 202	
(recognizing specific intracellular AAT polymers) showed a similar pattern for polymerization in 203	
AM and in liver sections of PiZZ AAT individuals (Fig.3 C-D). The percentage of AM that stained 204	
positive for polymers was increased not only in individuals with AATD, but also in smokers with or 205	
without COPD and normal AAT levels compared to non-smokers, where no polymerization was 206	
seen (Fig.4).  207	
When all cases were considered together, the cumulative exposure to cigarette smoke (packs/year) 208	
was positively correlated to the percentage of macrophages showing PAS+ inclusions 209	
(r=0.41;p=0.003) and those positive for AAT polymers (r=0.53;p=0.0001;e-Fig 1).  210	
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The score of small airways disease in COPD subjects with and without AATD was significantly 211	
higher than in the smokers without COPD and in non-smokers (Table 2). 212	
On macroscopic analysis both transplanted groups (with and without AATD) had severe diffuse 213	
emphysema with vast extension of lung destruction in both upper and lower lobes. Probably 214	
because of the vast extension of lung destruction in both upper and lower lobes, the type of 215	
macroscopic emphysema (CLE or PLE) was not clearly defined. The semi quantitative score of the 216	
extent of microscopic emphysema showed that cases with COPD, with and without AATD, had an 217	
increased emphysema score when compared with both smokers without COPD and non-smokers 218	
(Table 2). 219	
The number of lymphoid follicles/cm2 in COPD subjects with and without AATD were 220	
significantly higher than in the smokers without COPD and in non-smokers (Table 2), as did the 221	
number of B and CD4+ and CD8+ lymphocytes in the alveolar wall (Table 2). 222	
When we examined the relationship between the presence of polymerized AAT in alveolar 223	
macrophages and the lung pathology we found that the percentage of polymerized alveolar 224	
macrophages correlated significantly with the emphysema score (r=0.55;p=0.002), the small airway 225	
disease score (r=0.44;p= 0.004;e-Fig 2), and the numbers of neutrophils (r=0.31;p=0.05) and also 226	
with the number of CD8+T lymphocytes (r=0.51;p=0.002;e-Fig 3). Furthermore, the percent of 227	
polymerized AM was inversely correlated with pulmonary function parameters (FEV1: r=-228	
0.44;p=0.002 and FEV1/FVC: r=-0.41;p=0.005). 229	
In liver tissue there was a positive correlation between the score of polymerization and that of 230	
infiltration of inflammatory cells (CD45) (r=0.56;p<0.0001).  231	
  232	
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Discussion 233	
 234	
Alveolar macrophages are highly prevalent within the lung and can produce considerable amounts 235	
of AAT. We investigated if polymerization due to misfolding, aggregation and retention of 236	
abnormal Z-AAT that takes place in liver cells, could also occur in alveolar macrophages. Our 237	
results showed that AAT polymers are present in alveolar macrophages in the lung of individuals 238	
with PiZZ AAT deficiency (COPD with AATD). Surprisingly, we also found AAT polymers in 239	
alveolar macrophages of smokers with COPD and normal AAT levels (“usual” COPD) and in 240	
smokers without COPD, but not in non-smokers.  241	
The presence of significant polymerization of AAT in human alveolar macrophages directly in 242	
human lung tissue had never been previously reported. Perhaps alveolar macrophage polymers are 243	
the source of the bronchoalveolar lavage (BAL) polymers previously described in individuals with 244	
PiZZ AAT deficiency.30 We have found that periodic acid-Schiff (PAS) positive granules, possibly 245	
representing protein polymers, can be seen in alveolar macrophages by light microscopy. With the 246	
use of a specific antibody we showed that the PAS positive granules present in both PiZZ and 247	
PiMM AAT alveolar macrophages are, at least in part, due to AAT polymerization. There was a 248	
large variation in the percentage of macrophages showing AAT polymerization (ranging from 0 to 249	
55%), possibly because some polymers might be too small to be detected (polymers can vary in size 250	
from 2 to many molecules which can aggregate to form the visible granules).31 In addition, this 251	
variation could also depend on the alveolar macrophages phenotype and their proportion in the 252	
lung, since antiinflammatory M2 macrophages have been shown to express higher AAT mRNA, 253	
and thus potentially more polymerization, than proinflammatory M1 macrophages.32  254	
AAT contribution by alveolar macrophages. 255	
The polymerization of AAT within lung alveolar macrophages can have severe consequences for 256	
lung homeostasis and the development of emphysema associated with AAT deficiency. Liver 257	
produces wild-type M-AAT that diffuses through the endothelial barrier of the lung providing 258	
alveolar concentration of 10-15% of the plasma AAT level,33-35 and this concentration would be 259	
significantly supplemented by the secretion of AAT from alveolar macrophages.14 It has been 260	
calculated that there are approximately 20x109 lung alveolar macrophages which produce three 261	
times more AAT than bone marrow derived circulating monocytes,14 either because they are 262	
already programed in the fetal liver, or because they are reprogramed by the lung micro-263	
environment promoting the more efficient and/or increased production. The fact that alveolar 264	
macrophages reside directly at the site where AAT functions as an antiprotease and modulator of 265	
inflammation, suggests a specific differentiation of these cells and highlights their important 266	
contribution to the maintenance of lung homeostasis and its failure in deficient states. 267	
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Mechanisms of AAT polymerization in the lung. 268	
It has been clearly demonstrated that under stimulation PiMM and PiZZ alveolar macrophages 269	
produced similar AAT mRNA levels,14 however PiZZ alveolar macrophages produced 10 times less 270	
AAT protein than PiMM alveolar macrophages. This suggests that the defect is at the secretory 271	
level, and that the secretory defect secondary to protein misfolding and polymerization seen in the 272	
liver, is also present in alveolar macrophages. Unexpected was the finding, never reported before, 273	
of AAT polymers in the alveolar macrophages of smokers with COPD and normal AAT levels 274	
(“usual” COPD) and also in smokers without COPD, but not in non-smokers. All inhibitory 275	
SERPINS can be induced to polymerize by high temperature, oxidation and incubation with 276	
denaturants.31 These agents perturb the structure of AAT, opening b-sheet A-sheet to allow 277	
polymerization, although the rate of polymer formation is slower in wild-type M than mutant Z 278	
AAT. It has been shown that cigarette smoke can greatly accelerate PiZ-AAT polymerization and 279	
oxidize PiM-AAT in mice and human plasma36 that is in keeping with the association between 280	
cigarette smoking and polymerization reported in our study. This may explain our novel finding of 281	
AAT polymers present in alveolar macrophages from smokers with normal levels of AAT. 282	
Possible consequences of AAT polymerization. 283	
The lung disease seen in individuals with PiZZ AAT deficiency is usually thought as secondary to 284	
the low levels of circulating liver-produced AAT, to which we can now add the loss of the AAT 285	
secreted by the alveolar macrophages due to AAT polymerization. Furthermore, AAT 286	
polymerization could also contribute to the mechanism of disease by triggering important pro-287	
inflammatory effects. It has been previously reported that polymers of AAT in BAL from 288	
individuals with PiZZ AAT deficiency30 are chemotactic for human neutrophils in vitro and in 289	
mouse models of disease.37-39 Along with a “loss of AAT function” there may be an additional 290	
“toxic gain of function” originating from the accumulation of misfolded and aggregated AAT in 291	
alveolar macrophages endoplasmic reticulum (ER), which could induce ‘ER stress’ and the 292	
consequent, unfolded protein response (UPR) that normally ensures that misfolded proteins are 293	
removed for degradation. However chronic ER stress could tip the UPR from been adaptive to 294	
promoting inflammation.40 Although we have not studied this possibility, the induction of UPR 295	
secondary ER stress in blood monocytes from PiZZ AAT individuals41 and in bone marrow derived 296	
macrophages42 has been shown to potentiate pro-inflammatory signaling, including the induction of 297	
genes encoding CXC-chemokine ligand 1 (CXCL1) CXCL2, TNF, IL-1, and IL-6.41 298	
Likely the following events could plausibly take place in the lungs of smokers with and without 299	
AAT deficiency (Fig.5): inflammatory stimuli, cigarette smoke, free elastase, elastase-AAT-300	
complexes would stimulate an increase production of AAT in alveolar macrophages, which could 301	
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misfold and polymerize in the endoplasmic reticulum causing endoplasmic reticulum stress and 302	
activation of the UPR. As in a vicious circle (Fig.5), UPR activation by increasing the production of 303	
pro-inflammatory cytokines and chemokines, such as IL-6, would increase the inflammation that 304	
will induce further AAT production, further misfolding and retention in macrophages endoplasmic 305	
reticulum perpetuating the endoplasmic reticulum stress. Other local factors such as local hypoxia, 306	
as seen in COPD, could add to ER stress. The correlation between the extent of polymerization and 307	
the severity of inflammation in lung and liver is in support of this hypothesis. Similar mechanisms 308	
are thought to play an important role in autoimmune diseases such as inflammatory bowel disease 309	
and rheumatoid arthritis.43-45 310	
If this were the case ER stress would be an important added stimulus and contributor to the innate 311	
and adaptive immune inflammation that we have described in severe PiZZ AAT deficiency and in 312	
“usual” COPD.25 Importantly, ER stress does not always induce inflammation since cellular 313	
adaptation to chronic ER stress can also suppress the inflammatory response to unfolded protein 314	
(UPR).46,47 How cells decide between proinflammatory and anti-inflammatory UPR signaling is 315	
poorly understood. This phenomenon could perhaps explain why AAT polarization is seen in our 316	
population of smokers without COPD, who have less lung inflammation. 317	
The findings described emphasize the complex role that could be played by the molecular 318	
abnormalities of AAT in the development of COPD and emphysema and highlights another 319	
important and potentially damaging effect of cigarette smoking. Our findings also highlight the 320	
similarities, ever more evident, in the pathophysiology of COPD in smokers with and without AAT 321	
deficiency and add another potentially important step to the complex mechanism underlying COPD. 322	
Conclusion 323	
Polymerization of AAT in alveolar macrophages occurs in the lungs of individuals with AATD but 324	
also in smokers with normal AAT levels with or without COPD. Our findings highlight the 325	
similarities in the pathophysiology of COPD in individuals with and without AATD, adding a 326	
potentially important step to the mechanism of COPD.  327	
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Table1: Clinical characteristics of the subjects in the study cohort. 477	
 478	
Definition of abbreviations: AATD = α1-antitrypsin deficiency; COPD = chronic obstructive 479	
pulmonary disease; “usual” COPD = COPD with normal AAT levels; 480	
Values are expressed as the means±SD. 481	
† Significantly different from smokers without (w/o) COPD and non-smokers (p<0.0001). 482	
  483	
 COPD with AATD 
Usual 
COPD 
Smokers w/o 
COPD 
Non 
Smokers 
Number of subjects, n 9 24 11 13 
Age, years 53±3 57±1 62±2 56±6 
Smoking history, 
pack-years 34±8 41±7 48±7 - 
Current/ex-smokers, n 0/9 2/22 4/7 - 
FEV1, % pred 19±2† 20±2† 98±3 108±5 
FEV1/FVC, % 35±5† 37±3† 77±2 85±4 
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Table 2: Quantification of lung pathology and inflammation.  
 COPD with 
AATD 
Usual 
COPD 
Smokers w/o 
COPD 
Non 
Smokers 
Small airways disease 
(score %) 
78(43-92)** 67(33-100)** 26(0-63) 17(0-50) 
Emphysema (score %) 83(67-100)** 84(33-100)** 0(0-17) 0(0-0) 
Lymphoid follicles/cm2 4.6 (0.7-16.5)** $ 1.5(0-6.1)** 0(0-2.5) 0(0.0-0.8) 
B cells/mm of alveolar 
wall 
2.1(0-4.4)** 0.9(0-5.0)** 0.2(0-0.63) 0.3(0-0.9) 
CD4+ cells/mm of 
alveolar was 
5.5(0.9-10.8)* 6.1(1.6-11.9)* 2.26(0.2-4) 2.1(0-5.4) 
CD8+ cells/mm of 
alveolar wall 
3.4(0.6-6.8)§ 4.1(3.0-6.8)* 3.4(0.6-5.1) 2.1(0-5.2) 
Neutrophils/mm of 
alveolar wall 
6.3(1.2-15.9) 9.4(4.5-13.9) § 6.8(2.5-9.5) 3.8(0-15.1) 
 484	
Definition of abbrevetions: AATD = a1-antitrypsin deficiency; COPD = chronic obstructive 485	
disease; usual COPD: COPD with normal AAT levels. 486	
Values are expressed as median(range).  487	
*or** Significantly different from smokers without (w/o) COPD and non-smokers (*p<0.05 or 488	
**p<0.01) 489	
$ Significantly different from usual COPD (p<0.05) 490	
§	Significantly different from non-smokers (p<0.05) 491	
 492	
  493	
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Figure Legends:  494	
 495	
Figure1. Total (native and polymerized) α1-antitrypsin (AAT) immunostaining in alveolar 496	
macrophages. Quantification of AAT expression in alveolar macrophages of patients with chronic 497	
obstructive pulmonary disease and α1-antitrypsin deficiency (COPD with AATD), “usual” COPD 498	
(COPD with normal AAT levels), smokers without COPD, and non-smokers. 499	
(A) Representative examples of AAT expression in the lung of a COPD patient with AATD, and 500	
(B) in the lung of a non-smoker. Positive staining (in brown) was mainly observed in alveolar 501	
macrophages and occasionally in the alveolar wall. Immunostaining with polyclonal antibody 502	
IR505 anti-AAT (A and B). Scale bars = 40 µm. 503	
(C) The percentage of alveolar macrophages positive for AAT was not significantly different 504	
among the four groups of subjects examined. Horizontal bars represent median values.  505	
 506	
Figure 2. PAS staining in alveolar macrophages. Quantification of PAS expression in alveolar 507	
macrophages of patients with COPD and α1-antitrypsin deficiency (COPD with AATD, “usual” 508	
COPD (COPD with normal AAT levels), smokers without COPD, and non-smokers. 509	
(A) Representative examples of PAS expression in the lung of a COPD patient with AATD, and (B) 510	
in the lung of a non-smoker. Positive staining (in violet) was mainly observed in alveolar 511	
macrophages; arrow indicate PAS positive inclusion. Scale bars = 30 µm. 512	
(C) The percentage of PAS positive alveolar macrophages was increased in patients with AATD, 513	
and in smokers with and without COPD compared to non-smokers. Furthermore, the percentage of 514	
alveolar macrophages positive for PAS was increased in “usual”COPD compared to smokers 515	
without COPD. P values in the figure represent Mann–Whitney U tests. Kruskal–Wallis test: 516	
p<0.0001. Horizontal bars represent median values. 517	
 518	
Figure 3. PAS staining and immunostaining for AAT polymers in liver and lung sections of 519	
AATD patients. (A and B) Representative examples of PAS expression in the liver of a patient 520	
with AATD (A) and in the lung (B) of a COPD patient with AATD. Positive PAS staining in violet. 521	
(C and D) Representative examples of AAT polymers expression in the liver of a patient with 522	
AATD (C) and in the lung (D) of a COPD patient with AATD. Positive immunostaining with 523	
specific monoclonal antibody 2C1 specific for AAT polymers in brown (C and D). A-C: Scale bars 524	
= 30 µm. D: Scale bars = 15 µm. 525	
 526	
Figure 4. α1-antitrypsin (AAT) polymers in alveolar macrophages. Quantification of AAT 527	
polymers expression in alveolar macrophages of patients with COPD and α1-antitrypsin deficiency 528	
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(COPD with AATD), “usual” COPD (COPD with normal AAT levels), smokers without COPD, 529	
and non-smokers. 530	
(A) Representative examples of AAT polymers expression in the lung of a COPD patient with 531	
AATD and (B) in the lung of a non-smoker. Positive staining (in brown) was mainly observed in 532	
alveolar macrophages; arrows indicate AAT positive polymers. Immunostaining with monoclonal 533	
antibody 2C1 anti-AAT polymerized (A and B). Scale bars = 30 µm. 534	
(C) The percentage of alveolar macrophages positive for AAT polymerized was increased in COPD 535	
patients with AATD, in “usual” COPD and in smokers without COPD compared to non-smokers. P 536	
values in the figure represent Mann–Whitney U tests. Kruskal–Wallis test: p<0.0001. Horizontal 537	
bars represent median values. 538	
 539	
Figure 5. The pathway of lung inflammation induced by AAT polymerization. The 540	
inflammatory response induced by smoking would upregulate α-1ATmRNA in alveolar 541	
macrophages. This would increase AAT production that could misfold and polymerize in the 542	
Endothelial Reticulum (ER) causing ER stress that, with the enhancement of a “second hit” by 543	
cigarette smoke causes activation of the Unfolded Protein Response (UPR). As in a vicious circle 544	
UPR activation would further increase the expression of pro-inflammatory genes and lung 545	
inflammation, which would induce further AAT production. Furthermore, the chemotactic role of 546	
AAT polymers will attract neutrophils further increasing the inflammatory response, all 547	
contributing to the worsening of the disease.  548	
